Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000992217 | SCV001144300 | uncertain significance | not provided | 2018-12-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002067593 | SCV002453531 | likely benign | Developmental and epileptic encephalopathy, 32 | 2021-06-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004030137 | SCV004889914 | uncertain significance | Inborn genetic diseases | 2024-03-01 | criteria provided, single submitter | clinical testing | The c.1433A>G (p.K478R) alteration is located in exon 3 (coding exon 1) of the KCNA2 gene. This alteration results from a A to G substitution at nucleotide position 1433, causing the lysine (K) at amino acid position 478 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |